Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation
- 1 September 1999
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 48 (3), 388-394
- https://doi.org/10.1046/j.1365-2125.1999.00006.x
Abstract
Aims To investigate whether or not there is a correlation between failure to respond to typical antipsychotics and CYP2D6 ultrarapid metaboliser status. Methods CYP2D6 phenotype (metaboliser status) was assigned following genotyping for gene duplication, as well as for the CYP2D6*3, CYP2D6*4, and CYP2D6*5 null alleles in 235 treatment-refractory patients and 73 nonrefractory patients. Results Four (1.7%) of the 235 treatment-refractory subjects were positive on the duplication assay, but, of these, two were found to represent duplications of a null allele (CYP2D6*4 ), therefore leaving only two (0.85%) positive for duplication of a wild type allele (ultrarapid metabolisers). Three (4.1%) of the nonrefractory subjects had a genotype consistent with ultrarapid metaboliser status. Fisher’s exact test gave a two-tailed P value of 0.091, i.e. a trend towards an excess of ultrarapid metabolisers in the nonrefractory group, which was in the opposite direction to that predicted by our hypothesis. Conclusions Although the results show a trend towards an excess of ultrarapid metabolisers in the nonrefractory group, the percentages in the two groups of patients are both within the range for ultrarapid metabolisers in Caucasian populations. Our data are not consistent with ultrarapid metaboliser status being a major cause of failure to respond to typical antipsychotics.This publication has 40 references indexed in Scilit:
- The Lilly Prize Lecture 1996 ‘Keep on taking the tablets’: pharmacological adaptation during long-term drug therapyBritish Journal of Clinical Pharmacology, 1997
- Ultrarapid metabolizers of debrisoquine: Characterization and PCR‐based detection of alleles with duplication of the CYP2D6 geneFEBS Letters, 1996
- PCR-based genotyping for duplicated and deleted CYP2D6 genesPharmacogenetics, 1996
- Psychobiologic correlates of treatment response in schizophreniaNeuropsychopharmacology, 1996
- Psychopathological syndromes in the functional psychoses: associations with course and outcomePsychological Medicine, 1996
- The content and context of complianceInternational Clinical Psychopharmacology, 1995
- Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean populationPharmacogenetics, 1993
- Genetically variable metabolism of antidepressants and neuroleptic drugs in manPharmacogenetics, 1993
- A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia: With particular reference to drug resistanceSchizophrenia Research, 1993
- Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquineThe Lancet, 1993